Quick Search
Sitagliptin Add-on to Metformin Plus Sulphonylurea Combination Therapy: The Efficacy of Triple Therapy on Metabolic and Glycemic Control in Type 2 Diabetes
Savaş Volkan Kısıoğlu1, Ozgur Can2, Sakin Tekin3, Mehmet Sargin41Department of Endocrinology, Trabzon Kanuni Training and Research Hospital,Trabzon, Turkey2Department of Nephrology, Bitlis Tatvan State Hospital, Bitlis, Turkey
3Department of Endocrinology, Zonguldak Bulent Ecevit University, Zonguldak, Turkey
4Department of Family Medicine, Istanbul Medeniyet University, Goztepe Training and Research Hospital, Istanbul, Turkey
INTRODUCTION: This study aimed to evaluate the efficacy of sitagliptin add-on metformin and sulphonylurea combination therapy in type 2 diabetic patients with insufficient glycemic control.
METHODS: This study included who were treated with sitagliptin and continued with sitagliptin for 12 months while receiving metformin-sulphonylurea combination. The fasting plasma glucose (FPG) and hemoglobin A1c (HbA1c) levels of the patients were measured at the initial, 3rd month, 6th month and 12th month.
RESULTS: A total of 40 patients were included in this study. The mean age patients was 59.2±9.6 years and initial HbA1c level was 7.6% (7.0-10.5). The HbA1c level of the patients was 6.8% (5.9-8.7) at 3 months, 6.7% (5.3–7.5) at 6 months, and 6.9% (5.4–9.1) at 12 months (p<0.001 for 0-3. months, p<0.001 for 0-6. months, p=0.003 for 0-12. months).
DISCUSSION AND CONCLUSION: Adding sitagliptin to the treatment is an effective and well-tolerated option in patients with type 2 diabetes who are not able to achieve adequate glycemic control despite metformin–sulphonylurea combination treatment.
Manuscript Language: English